Leier C V, Patrick T J, Hermiller J, Pacht K D, Huss P, Magorien R D, Unverferth D V
Am Heart J. 1984 Dec;108(6):1461-8. doi: 10.1016/0002-8703(84)90693-8.
Ten patients with moderate to severe congestive heart failure (CHF) underwent central and regional hemodynamic measurements at rest and central hemodynamic measurements during exercise before and after the oral administration of nifedipine (0.2 mg/kg). Nifedipine significantly decreased systemic blood pressure, systemic vascular resistance, pulmonary artery pressure, pulmonary vascular resistance, and pulmonary capillary wedge pressure. Stroke volume and cardiac output increased after nifedipine. The measured parameters of left ventricular inotropy did not change significantly for this calcium channel blocker. While blood flow to renal, hepatic, and limb vascular beds increased (p less than 0.05 for renal and limb) after nifedipine, only limb blood flow increased in proportion to the increase in cardiac output, suggesting preferential dilatation of limb vasculature. Although initial-dose nifedipine did not increase exercise duration, it elicited an improvement in exercise hemodynamics by reducing systemic vascular resistance and pulmonary capillary wedge pressure and increasing stroke volume and cardiac output. The calcium channel blocker, nifedipine, can be administered safely in the setting of ventricular failure and appears to favorably alter resting and exercise hemodynamics. A select number of patients with CHF may benefit from its long-term administration.
10例中重度充血性心力衰竭(CHF)患者在口服硝苯地平(0.2mg/kg)前后,分别于静息状态下进行了中心和区域血流动力学测量,并在运动过程中进行了中心血流动力学测量。硝苯地平显著降低了体循环血压、体循环血管阻力、肺动脉压、肺血管阻力和肺毛细血管楔压。硝苯地平用药后,每搏输出量和心输出量增加。对于这种钙通道阻滞剂,左心室收缩性的测量参数没有显著变化。硝苯地平用药后,肾、肝和肢体血管床的血流量增加(肾和肢体的p值均小于0.05),但只有肢体血流量与心输出量的增加成比例增加,提示肢体血管优先扩张。虽然初始剂量的硝苯地平没有增加运动持续时间,但它通过降低体循环血管阻力和肺毛细血管楔压、增加每搏输出量和心输出量,改善了运动血流动力学。钙通道阻滞剂硝苯地平可在心力衰竭情况下安全给药,且似乎能有利地改变静息和运动时的血流动力学。部分CHF患者可能从长期给药中获益。